NCT04955262View on ClinicalTrials.gov

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

January 31, 2022

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

Bempegaldesleukin (NKTR-214)

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

DRUG

⁸⁹Zr-Df-IAB22M2C

Specified dose on specified days

Trial Locations (3)

19104

Investigational Site - Philadelphia, Philadelphia

91010

Investigational Site - Duarte, Duarte

97213

Investigational Site - Portland, Portland

Sponsors

Collaborators (1)

ImaginAb, Inc.
All Listed Sponsors
collaborator

ImaginAb, Inc.

INDUSTRY

lead

Nektar Therapeutics

INDUSTRY